CurrentPremera BluecrossPolicy 1.01.508

Negative Pressure Wound Therapy (NPWT) Devices in Adults

Defines medical necessity, continuation, investigational status, documentation, coding, contraindications, and evidence considerations for powered and single-use NPWT systems in adults (age ≥19). Focus is outpatient use and therapeutic trial requirements.

Policy Summary

PayerPremera Bluecross

PolicyNegative Pressure Wound Therapy (NPWT) Devices in Adults

Policy CodePolicy 1.01.508

Change TypeNew policyannual reviewcode updates

Effective DateDec 4, 2025

Next Review DateMar 9, 2026

Key ActionDocument medical necessity criteria and objective wound improvement when requesting initial and continued authorization for powered NPWT.

SourceLink

POLICY UPDATE CHANGES

New policy 1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults approved August 12, 2025; effective 2025-12-04.

Annual Review approved March 9, 2026 updated literature through November 14, 2025 and added references; policy statements unchanged.

Codes added to policy section and HCPCS codes A7000 and A7001 removed (04/09/26).

Minor formatting update (09/16/25).

14 daysMinimum therapeutic trial

30 daysInitial approval period

97605-97608, A6550, A9272, E2402, K0743-K0746Key codes referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage summary

Policy 1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults — CURRENT; policy approved August 12, 2025 and effective for dates of service on or after 2025-12-04 after 90-day provider notification. Scope: defines medical necessity, continuation, investigational status, documentation, coding, contraindications, and evidence considerations for NPWT in adults (age ≥19), with a focus on outpatient use and therapeutic trial requirements.

Population/applicability: adults aged 19 and older (policy applies to adults; FDA clearance applies to ages ≥18) in the outpatient setting.

Overall coverage stance: Powered (durable) NPWT is covered when specified medical necessity criteria are met (therapeutic trial and continuation requirements); single-use (disposable) NPWT systems are considered investigational/not covered.

Quick facts and key thresholds

Therapeutic trial durationNot less than 14 days (2 weeks)

Initial/authorization periodInitial approval may be for 30 days

Re-authorization periodRe-authorization may be approved for additional 30-day periods with documented objective improvement

High-volume drainage definitionExudate exceeding 150 - 200 mL/day that overwhelms dressings and hinders healing

Morbid obesity BMI thresholdBMI ≥40 kg/m² with poor perfusion and elevated wound complication risk

PopulationApplies to adults aged ≥19

Policy effective dateEffective for dates of service on or after 2025-12-04

Last annual reviewAnnual Review approved March 9, 2026 (literature through Nov 14, 2025)

Medical necessity — powered NPWT

Single-use NPWT systems (investigational)

Evidence on single-use NPWT (portable/disposable systems) includes randomized trials showing noninferiority to standard or traditional NPWT for wound area reduction in some studies (for example, PICO and SNaP trials), but limitations such as high loss to follow-up, exclusions, and small sample sizes prevent definitive conclusions about improvements in net health outcomes.

As summarized in the evidence review, these RCTs demonstrated noninferiority for wound size reduction but the overall evidence is insufficient to determine that single-use NPWT results in an improvement in net health outcome across indications.

Coverage stance in the brief is mixed: single-use NPWT systems are designated investigational in the policy despite some trials showing noninferiority for intermediate outcomes.

Codes referenced in policy

Covered CPT (powered NPWT sessions)CPTCovered

97605	Negative pressure wound therapy, durable medical equipment, per session; total wound(s) surface area ≤ 50 sq cm
97606	Negative pressure wound therapy, durable medical equipment, per session; total wound(s) surface area > 50 sq cm

Investigational/Not covered CPT (single-use NPWT)CPTExperimental

97607	Negative pressure wound therapy, disposable, non-durable equipment, per session; total wound(s) surface area ≤ 50 sq cm
97608	Negative pressure wound therapy, disposable, non-durable equipment, per session; total wound(s) surface area > 50 sq cm

HCPCS / DME / supply codes referencedHCPCS

A6550	Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories
A9272	Wound suction, disposable, includes dressing and all accessories and components, any type, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable
K0743	Suction pump, home model, portable, for use on wounds
K0744	Absorptive wound dressing for use with suction pump, home model, portable, pad size ≤ 16 sq in
K0745	Absorptive wound dressing for use with suction pump, home model, portable, pad size >16 sq in but ≤48 sq in
K0746	Absorptive wound dressing for use with suction pump, home model, portable, pad size >48 sq in

HCPCS / DME codes (mentioned as added/removed in history)HCPCS

A9272	Introduced to policy on 01/25/12 (historical inclusion).
A7000	Removed from policy (04/09/26).
A7001	Removed from policy (04/09/26).

Actions and documentation requirements for providers

Documentation Required

Document indication and prior wound care

Document reason for powered NPWT and include a clear clinical history and physical exam that supports medical necessity. Chart documentation should summarize: wound history (duration and prior treatments), wound stage (e.g., Stage III or IV), size and depth, presence and volume of drainage, inability to maintain standard dressings due to anatomic factors, recent changes or complications, comorbidities that impair healing (e.g., diabetes, malnutrition, small vessel disease, morbid obesity) and evidence that comorbid conditions that impair healing (notably malnutrition) are being addressed. Include justification that prior optimal wound care was attempted and failed when applicable, and cite qualifying examples from the clinical criteria (chronic >90 days pressure ulcers failing optimal care; nonhealing ≥30 days with identified comorbid conditions; traumatic/surgical wounds with failed closure; exposed bone/cartilage/tendon/foreign material).

Required chart elements: history of present wound, prior wound care measures and response, physical exam with wound stage/measurements, documented drainage volumes (high-volume drainage defined in policy), reasons standard dressings cannot be maintained, relevant comorbidities and treatments addressing them (e.g., nutritional interventions).
Qualifying examples to reference in documentation: chronic Stage III/IV pressure ulcer >90 days failed optimal care; nonhealing wound ≥30 days with diabetes, malnutrition (with simultaneous treatment), small vessel disease, or BMI ≥40 with poor perfusion; traumatic/surgical wound with failed primary closure; wounds with exposed bone/cartilage/tendon/foreign material.

Background, evidence, and definitions

Background: Negative Pressure Wound Therapy (NPWT) uses suction to remove exudate, debris, and infectious material from the wound bed to promote granulation tissue formation and wound healing. The mechanism is hypothesized to include removal of interstitial fluid, increased wound vascularity, reduced edema, and beneficial mechanical forces that stimulate cell growth.

Device types: NPWT devices include powered durable pumps (stationary or portable electrical pumps) and single-use disposable systems (mechanical/portable disposable cartridges). Policy emphasizes powered NPWT delivered with durable equipment (CPT 97605/97606) versus disposable single-use systems (CPT 97607/97608).

Outpatient focus: The policy and evidence review concentrate on use in the outpatient setting; patients may begin therapy inpatient prior to outpatient transition.

Safety and regulatory: The FDA has issued safety communications (2009 update and 2011 alert) noting rare but serious complications including bleeding (the most serious adverse events, including deaths) and injuries from retained dressing pieces. The FDA cautions careful patient selection, frequent monitoring by trained practitioners, and vigilance for complications during dressing changes.

Comprehensive care: Powered NPWT should be used as part of a comprehensive wound care program addressing comorbid factors (e.g., diabetes control, nutritional status, relief of pressure); therapeutic trials should be accompanied by concurrent management (for example, malnutrition must be addressed simultaneously).

Coding note: Policy references specific CPT and HCPCS/DME codes for powered and single-use NPWT and related supplies to guide billing and coverage determinations.

Topic	Evidence summary
Diabetic foot ulcers - powered NPWT RCTs/systematic reviews	Evidence shows higher wound healing rates and fewer amputations with powered NPWT in diabetic lower‑extremity ulcers and amputation wounds, though trials had risk of bias; considered sufficient to show some clinical benefit.
Single-use NPWT portable systems	Randomized trials show noninferiority for wound area reduction for some single‑use systems (e.g., PICO, SNaP) but limitations (loss to follow‑up, exclusions) leave overall evidence insufficient to determine a consistent net health‑outcome benefit.
Chronic pressure ulcers	RCTs and systematic reviews are low quality or at high risk of bias; evidence is insufficient to determine improvement in net health outcomes for chronic pressure ulcers treated with NPWT.
Randomized trials and systematic reviews cited	Multiple randomized trials and systematic reviews (including Cochrane reviews and RCTs reported in JAMA and wound journals) are referenced as the primary evidence base.
Recent literature review cutoff	Literature review for the policy was updated through November 14, 2025.

Medicare determinations

Determination	Notes
No national coverage determination (NCD)	Medicare: there is no national coverage determination for NPWT devices.

Revision history and material changes

August 12, 2025policy_approval

New policy 1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults approved August 12, 2025; effective for dates of service on or after December 4, 2025 following 90-day provider notification.

2025-12-04effective_date

Policy effective for dates of service on or after December 4, 2025 per 90-day provider notification associated with the August 12, 2025 approval.

09/16/2025formatting_update